Skip to main content
R
NeighborhoodReport

Lake Medlock Dr

Alpharetta, GA 30022 Upscale Large Neighborhood
57
Homes
1
Streets
$583,005
Avg Home

Address Directory Page 1/2

Showing 1–50 of 57 addresses

1 0 Lake Medlock Dr

Owner: Levine Edward F & Victoria K

2 510 Lake Medlock Dr

Owner: Chen Baisha & Lai Yinuo

3 515 Lake Medlock Dr

Owner: Smith Katherine C

4 525 Lake Medlock Dr

Owner: Kumar Virender & Punia Ankita
Officer - C4 Group, INC. 1 business

5 530 Lake Medlock Dr

Owner: Levine Edward F & Vicki K
1 vehicle

6 535 Lake Medlock Dr

Owner: Wilson Isaiah & Tonya
1 vehicle CFO - Graphic Craft Corporation Nonprofit

7 540 Lake Medlock Dr

Owner: Rolader Lilis K
PPP $93,117 Officer - Packaged Construction Solution...

8 550 Lake Medlock Dr

Owner: Kothari Bharat R & Neelam B

9 555 Lake Medlock Dr

Owner: Han Won Ill & Kim Kwang Sun
Officer - Iteachcs, LLC

10 560 Lake Medlock Dr

Owner: Tyagi Anubhav Kumar & Akansha
PPP $40,500 3 vehicles

11 565 Lake Medlock Dr

Owner: Kim Susan H & Kim Herbert K

12 570 Lake Medlock Dr

Owner: Yeh Hwang Lih Yuh

13 575 Lake Medlock Dr

Owner: Voswinkel Patrick J & Eunice A
Officer - Ivy Falls Family Medicine INC

14 580 Lake Medlock Dr

Owner: Nguyen Paul Huy Dao & Dang Tiffany Bich Thanh

15 590 Lake Medlock Dr

Owner: Mei Chunfang & Li Suqin

16 595 Lake Medlock Dr

Owner: Li Ying Heng & Ling Ling
1 vehicle

17 600 Lake Medlock Dr

Owner: Du Chenggang & Luo Hong
1 business

18 605 Lake Medlock Dr

Owner: Daunais James & Daunais Kathryn
2 vehicles

19 615 Lake Medlock Dr

Owner: Grimes Jay R & Stacy P
Officer - Idearchitect Incorporated

20 630 Lake Medlock Dr

Owner: Coffman Christian D & Coffman Jill S

21 645 Lake Medlock Dr

Owner: Ravindran Aravind Kumar & Kumar Sowmya Priya Aravind
Officer - Red Leaf Partners, LLC 1 business

22 650 Lake Medlock Dr

Owner: Taylor Jan H & White Lawrence B
Officer - Chakra Enterprises, LLC

23 655 Lake Medlock Dr

Owner: Liang Kun & Lu Jiuxiao

24 670 Lake Medlock Dr

Owner: Xie Yunhong & Mao Hui
1 vehicle 1 business Fed Grant

25 675 Lake Medlock Dr

Owner: Jyotishi Rajesh C & Pari Rajesh
1 vehicle Officer - N3j, INC.

26 680 Lake Medlock Dr

Owner: Hoskote Seshagiri Rao & Kocherlakota Lakshmi Soujanya
2 vehicles Officer - Cyber Logic, INC. 1 business

27 690 Lake Medlock Dr

Owner: Sang Yoon Kim Living Trust The
3 vehicles CEO - Ozone Apparel Incorporated

28 710 Lake Medlock Dr

Owner: Dipillo John G & Dipillo Jacqueline R
2 vehicles

29 715 Lake Medlock Dr

Owner: Dixon Patrick Anthony & Dixon Jennifer Icia
1 vehicle

30 720 Lake Medlock Dr

Owner: Laura S Elvington Living Trust The

31 730 Lake Medlock Dr

Owner: Fambrough Franklin Eric & Fambrough Elizabeth Cooksey
1 vehicle

32 740 Lake Medlock Dr

Owner: Trivedi Priyanka & Bhatt Kumar Gaurav
1 vehicle Secretary - Baps Software Consulting Servi...

33 750 Lake Medlock Dr

Owner: Scott Bradley F & Scott Lori A

34 760 Lake Medlock Dr

Owner: Howell Christopher
Officer - Ibullet Systems, INC.

35 765 Lake Medlock Dr

Owner: Amy Ruth Jolley Mccrary Revocable Trust
1 vehicle

36 770 Lake Medlock Dr

Owner: Kay Julie M
1 vehicle

37 780 Lake Medlock Dr

Owner: Menardi Robert D & Menardi Elizabeth M
2 vehicles

38 785 Lake Medlock Dr

Owner: Truelove Randi E
Officer - Celebrity Image Art Gallery LL...

39 790 Lake Medlock Dr

Owner: Wilson Derrick A & Williams Wilson Kymber N
4 vehicles CFO - Ukrainian Association Of Georg...

40 795 Lake Medlock Dr

Owner: David & Phoebe Knox Revocable Trust The

41 800 Lake Medlock Dr

Owner: Song Kyung Sil & James
Officer - Studio Seven Thirteen Incorpor...

42 805 Lake Medlock Dr

Owner: Kim Sae Byul

43 810 Lake Medlock Dr

Owner: Goldsmith Family Living Trust The
1 vehicle

44 820 Lake Medlock Dr

Owner: Askinas Andrew A & Doan Cynthia L
2 vehicles

45 830 Lake Medlock Dr

Owner: Mastrototaro William
2 vehicles

46 835 Lake Medlock Dr

Owner: Tie Nanfeng

47 840 Lake Medlock Dr

Owner: Minnaugh Robert P & Teresa A

48 850 Lake Medlock Dr

Owner: Camardella John & Camardella Dorothy
1 vehicle

49 860 Lake Medlock Dr

Owner: Biondo Michael
PPP $20,916 Officer - Mike C Biondo, LLC.

50 865 Lake Medlock Dr

Owner: Hornsby Christopher L & Hornsby Shanna A
Officer - Icing On The Cake Events, LLC

Source: County assessor records, public records & state business filings · Updated Feb 2026

Loading map...

Commercial Fleet Presence

FMCSA Motor Carrier Registry

Industrial
200
Carriers
508
Power Units
519
Drivers
2.5
Avg Fleet
For-Hire: 122
Private: 78
Passenger: 6
Largest Carriers in ZIP
ROAD READY CARGO LLC
DOT #3621163 · Interstate
55 units
60 drivers
KEAD INVESTORS
DOT #4248961 · Intrastate
49 units
1 drivers
VOYAGER
DOT #3937975 · Interstate
34 units
34 drivers
INDIA TRANSPORT INC
DOT #2465704 · Interstate
15 units
15 drivers
BLACK EAGLE TRANSPORTATION INC
DOT #3354835 · Interstate
14 units
11 drivers

200 registered motor carriers in this ZIP. operating 508 power units. 122 for-hire carriers.

Explore Nearby in Alpharetta

Discover other neighborhoods in Alpharetta, GA and compare what they have to offer.

EPA Regulated Facilities

EPA Facility Registry Service

Very High
8
< 1 Mile
154
< 3 Miles
500
< 5 Miles
High
Concern
Facility Categories
Hazardous Waste 27 Toxic Release 2 Superfund 1 💨 Air Emissions 6 💧 Water Discharge 1 🚰 Water Systems 4
Facilities of Concern
AMERICAN DIE TECHNOLOGY
AIR SYNTHETIC MINOR, ICIS-NPDES NON-MAJOR, RISK AND TECHNOLOGY REVIEW
2.75 mi
COGBURN RD SITE
SUPERFUND (NON-NPL)
2.98 mi
MIDSOUTH PAVING, INC. DBA MIDSOUTH AGGREGATES (FORSYTH QUARRY)
AIR SYNTHETIC MINOR, FORMAL ENFORCEMENT ACTION, ICIS-NPDES NON-MAJOR
3.09 mi

500 EPA-regulated facilities within 5 miles. 8 within 1 mile. 1 Superfund sites. 2 toxic release reporters. 27 hazardous waste generators. 4 water systems serve the area.

Federal Grants & Assistance

USAspending.gov grant awards to recipients in this neighborhood.

7 grant records found FY2024–2025
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
AGING RESEARCH
DEVELOPMENT OF "IMAGNOSTIX": A LIQUID BIOPSY SYSTEM FOR ALZHEIMER'S DISEASE - PROJECT SUMMARY DEVELOPMENT OF AD/ADRD MAY TAKE 15 TO 20 YEARS PRIOR TO SYMPTOMS. HOWEVER, CURRENT DIAGNOSIS AND DIFFERENTIATION OF AD/ADRD FROM OTHER DEMENTIAS AND EVEN COGNITIVE DECLINE ASSOCIATED WITH AGING IS MOSTLY SYMPTOM-BASED, HEAVILY RELYING ON NEUROLOGICAL AND COGNITIVE TESTS, FOLLOWED BY CONFIRMATION WITH BIOMARKER- SPECIFIC POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AND MOST RECENTLY DETECTION OF CHANGES IN AD BIOMARKERS IN CEREBROSPINAL FLUID (CSF). DELAYED DIAGNOSIS AND LACK OF TREATMENT OPTIONS TO SLOW OR REVERSE DISEASE PROGRESSION ARE MAJOR CHALLENGES IN MANAGING AD/ADRD, LARGELY DUE TO THE LACK OF EARLY AND ACCURATE DIAGNOSTIC. DETECTING AD AT PRODROMAL OR EVEN PRE-SYMPTOMATIC STAGE TO ALLOW TIMELY INTERVENTION HAS BEEN CONSIDERED THE BEST APPROACH TO MANAGE AD/ADRD. WHILE RECENT FDA-APPROVALS OF TWO DISEASE-MODIFYING DRUGS, I.E., ADUCANUMAB (ACCELERATED APPROVAL IN 2021) AND LECANEMAB (TRADITIONAL APPROVAL IN 2023), ALONG WITH THOSE IN THE PIPELINE, SUCH AS DONANEMAB FOR EARLY SYMPTOMATIC AD PARTICIPANTS8, ARE SIGNIFICANT ADVANCES THAT BROUGHT HOPE FOR MANY AD PATIENTS AND THEIR FAMILIES. THESE TREATMENTS ARE ONLY EFFECTIVE WHEN PATIENTS CAN BE DIAGNOSED AT AN EARLY STAGE AND PRESENT THE PATHOLOGY TARGETED BY THESE NEW DRUGS. THEREFORE, THERE IS AN URGENT DEMAND FOR BIOMARKER-BASED DETECTIONS FOR EARLY DIAGNOSIS FOR AD/ADRD, STRATIFICATION OF PATIENTS FOR TREATMENT AND MONITORING TREATMENT RESPONSES AND DISEASE PROGRESSION, IN PARTICULAR, COST-EFFECTIVE, EASY-TO- ACCESS AND REPEATABLE TESTS THAT CAN BE ROUTINELY APPLIED FOR PATIENTS AND THOSE WITH AD/ADRD RISKS. THE URGENT NEED OF BLOOD SAMPLE-BASED AD DIAGNOSIS PROMOTED FDA’S RECENT BREAKTHROUGH DEVICE DESIGNATIONS FOR TWO BLOOD-BASED AD DETECTION SYSTEMS, I.E., PRECIVITYAD® (2019) AND SIMOA® (2022). BOTH DETECTIONS REQUIRE BLOOD SAMPLE PROCESSING, STORAGE AND TRANSPORTATION, BEFORE MEASUREMENT USING HIGHLY SOPHISTICATED ANALYTIC INSTRUMENTS BY HIGHLY-SKILLED AND EXPERIENCE PERSONNEL, ALL OF WHICH CAN LIMIT THEIR AVAILABILITY AND COST- EFFECTIVENESS. THIS PHASE II SBIR PROJECT AIMS TO DEVELOP A MULTIPLEXED LIQUID BIOPSY, NAMELY IMAGNOSTIX, FOR DETECTION AND QUANTIFICATION OF FOUR AD BIOMARKERS. IMAGNOSTIX IS ANTICIPATED TO BE COST-EFFECTIVE, DEPLOYABLE, EASY TO OPERATE, AND CAPABLE OF QUICK TURN-AROUND TEST, WHILE STILL OFFERING A GOOD DETECTION SENSITIVITY. IT CAN BE USED FOR ROUTINE BLOOD TESTS OF INDIVIDUALS AT RISK, MONITORING OF DISEASE PROGRESSION OR TREATMENT RESPONSES, AND IN THE FUTURE, EVEN SCREENING AD/ADRD.
$888,723
PROJECT GRANT (B)
Sep 17, 2025
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
CARDIOVASCULAR DISEASES RESEARCH
MULTI-FUNCTIONAL MAGNETIC NANORODS FOR CONSTRUCTING THERANOSTIC EXTRACELLULAR VESICLES FOR TREATING MYOCARDIAL INFARCTION - PROJECT SUMMARY CARDIOVASCULAR DISEASE (CVD) REMAINS THE LEADING CAUSE OF DEATH AND A GLOBAL PUBLIC HEALTH BURDEN. MYOCARDIAL INJURY WITH INFARCTION (MI) IS A COMMON CVD THAT IS ASSOCIATED WITH HEART FAILURE AND EVEN DEATH. CELL-, ESPECIALLY STEM CELL (SC)-BASED THERAPIES HAS BEEN OF GREAT INTEREST FOR TREATING HEART DISEASES, BECAUSE 1) THE ADULT HEART HAS A LIMITED NUMBER OF SCS AND THUS LIMITED CAPACITY OF SELF-REPAIR AND REGENERATION, AND 2) CURRENT TREATMENT STRATEGIES ARE ONLY ABLE TO LIMIT THE ENSUING ADVERSE DILATATION AND IMPAIRED CONTRACTILE FUNCTION. HOWEVER, CLINICAL TRANSLATION OF SC-BASED THERAPIES REMAINS CUMBERSOME WITH VERY FEW SUCCESSES, IN A LARGE PART DUE TO THE SAFETY AND ETHICAL CONCERNS OVER UNCONTROLLABLE DIFFERENTIATION OF INJECTED CELLS IN PATIENTS. AS MOUNTING EVIDENCE REVEALS THE SC-INDUCED REPAIRING FUNCTIONS PREDOMINATELY DERIVED FROM THE PARACRINE EFFECT MEDIATED BY EXTRACELLULAR VESICLES (EVS), THERAPIES BASED ON SC-DERIVED EVS (SC-EVS) HAVE EMERGED AS A HIGHLY PROMISING APPROACH FOR CELL-FREE REGENERATIVE MEDICINE THAT DELIVERS HIGH POTENCY BUT LESS SIDE-EFFECT ASSOCIATED WITH CONVENTIONAL CELL-BASED THERAPY. A MAJOR LIMITING FACTOR TO THE EFFICACY OF EV-BASED TREATMENT IS THE EFFECTIVENESS OF EV DELIVERY TO TARGET TISSUES. INDEED, MOST ANIMAL STUDIES EMPLOYED DIRECT CARDIAC INJECTION IN ORDER TO ACHIEVE SIGNIFICANT TREATMENT EFFECTS, ALTHOUGH SYSTEMIC ADMINISTRATION IS MUCH PREFERRED IN THE CLINIC. MOREOVER, CLINICAL TRANSLATION OF NEW EV THERAPIES REQUIRES NON-INVASIVE IMAGING FOR MONITORING AND QUANTIFICATION OF EV DELIVERY AND TREATMENT RESPONSES INPATIENTS, WHICH HAVE NOT BEEN FULLY DEVELOPED YET. THE OVERALL GOAL OF THIS STTR PHASE I PROJECT TAKES AN IMPORTANT FIRST STEP TO TRANSLATE AN MRI-GUIDED, THERANOSTIC (THERAPEUTICS + DIAGNOSTICS) EV PLATFORM DEVELOPED IN THE RESEARCH LAB FOR EFFECTIVELY TREATING INJURED MYOCARDIUM IN ACUTE MI. THIS COLLABORATIVE PROJECT, BETWEEN 5M BIOMED AND KENNEDY KRIEGER INSTITUTE (KKI)/JOHNS HOPKINS UNIVERSITY (JHU), IS BUILT ON OUR INNOVATIONS IN MAGNETIC LABELING AND PURIFICATION OF THERAPEUTIC HUMAN SC-EVS, MRI-BASED EV TRACKING, AND ULTRA-MAGNETIC IRON OXIDE NANORODS (IONRS). WE WILL FOCUS ON DEVELOPING AND VALIDATING A TRANSLATABLE THERANOSTIC EV SYSTEM, USING MULTIFUNCTIONAL ULTRA-MAGNETIC IONRS THAT ARE SUITABLE FOR EFFICIENT MAGNETIC PURIFICATION/ENRICHMENT, MAGNETIC TARGETING, AND NON-INVASIVE MRI OF EVS. WE WILL COLLABORATE CLOSELY TO 1) DEVELOP AND OPTIMIZE ULTRA-MAGNETIC IONRS FOR EFFICIENT PREPARATION OF MAGEV WITH HIGH MRI CONTRAST EFFECT, AND 2) TEST AND VALIDATE THE DELIVERY AND EFFICACY OF MAGEV LABELED WITH IONRS IN IMAGING AND TREATING MI. THE BENCHMARK OF SUCCESS IS TO ACHIEVE AN OPTIMAL FORMULATION OF MAGEV, I.E., MINIMAL INTERFERENCE OF IONRS ON MAGEV FUNCTIONALITIES AND THERAPEUTIC POTENTIAL TOGETHER WITH HIGH MRI CAPABILITY AND MAGNETISM. THE SUCCESS OF PHASE I STUDY WILL LEAD TO THE PHASE II PROJECT, WHICH WILL FOCUS ON SCALE-UP MANUFACTURING OF MAGEVS TOWARDS INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND LARGE-ANIMAL TESTING WHICH WILL GUIDE SUBSEQUENT FIRST-IN-HUMAN STUDIES.
$306,433
PROJECT GRANT (B)
Nov 28, 2023
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH
SMALL INTESTINE TARGETED FAST ACTING ORAL INSULIN FORMULATION - PROJECT SUMMARY DIABETES MELLITUS IS A CLASS OF METABOLIC DISEASES CHARACTERIZED BY CHRONIC HYPERGLYCEMIA DUE TO IMPAIRED INSULIN SECRETION AND/OR INSULIN RESISTANCE. PATIENTS ARE SUBJECT TO LIFE-LONG MANAGEMENT OF THEIR DIABETIC CONDITIONS AND THE HIGH RISK OF MACRO AND MICROVASCULAR COMPLICATIONS. INSULIN THERAPY IS THE MOST EFFECTIVE MEANS OF LOWERING BLOOD GLUCOSE FOR TYPE 1 DIABETES MELLITUS (T1DM) PATIENTS WITH COMPLETE ABSENCE OF ENDOGENOUS INSULIN AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS WITH PROGRESSIVELY DEPLETED INSULIN SECRETING PANCREATIC Β-CELLS AND INSULIN RESISTANT ORGANS AND TISSUE. IT IS ALSO USED FOR CONTROLLING SHORT-TERM HYPERGLYCEMIA IN GESTATIONAL DIABETES MELLITUS (GDM). THE CURRENT THERAPY IS SUBCUTANEOUS INJECTION OR INFUSION OF INSULIN. HOWEVER, THE POOR PATIENT ADHERENCE DUE TO INCONVENIENCE AND PSYCHOLOGICAL INSULIN RESISTANCE (PIR) TO ROUTINE INJECTION IS STILL A MAJOR HINDRANCE IN MANAGING DIABETIC PATIENTS. FURTHERMORE, LONG- TERM USE OF INSULIN INJECTION CAN CAUSE SIDE EFFECTS, INCLUDING LIPODYSTROPHY, IATROGENIC HYPERINSULINEMIA, AND HYPOGLYCEMIA. ORALLY DELIVERED INSULIN, ON THE OTHER HAND, POSSESSES ADVANTAGES IN PATIENT ADHERENCE AND THERAPEUTIC EFFECT BY MIMICKING THE PHYSIOLOGICAL PATH OF ENDOGENOUS INSULIN. HOWEVER, THE DEVELOPMENT OF ORAL INSULIN FORMULATIONS HAS NOT YET BEEN SUCCESSFUL DUE TO LOW INSULIN BIOAVAILABILITY, STEMMING FROM THE DEGRADATION IN THE HIGHLY ACIDIC AND PROTEASE-ACTIVE STOMACH AND INSUFFICIENT PERMEABILITY THROUGH THE INTESTINAL EPITHELIUM AND MUCOSA. THIS STTR PHASE I PROJECT AIMS TO DEVELOP A FAST-ACTING ORAL INSULIN FORMULATION BASED ON THE PATENTED INNOVATION OF MILK PROTEIN CASEIN COATED DRUG-CARRYING NANOPARTICLES (CASNP) TO ENCAPSULATE INSULIN AND THE INTESTINAL ABSORPTION ENHANCER, SODIUM CAPRATE (C10), FOR SMALL INTESTINE-TARGETED DELIVERY OF INSULIN BY PROTECTING INSULIN AND C10 FROM THE GASTRIC PH AND PROTEASE ACTION BUT ENABLING THE ENZYME-TRIGGERED RELEASE OF INSULIN AND C10 IN THE SMALL INTESTINE. THE LIQUID FORMULATION OF NANO-SIZED CASNP/INSLULIN/C10 ALSO FACILITATES RAPID GASTRIC EMPTYING AND INTESTINAL PERMEATION AND ABSORPTION AS EXPECTED IN A FAST-ACTING ORAL INSULIN AGENT FOR CONTROLLING THE POSTPRANDIAL BLOOD GLUCOSE LEVELS. DEVELOPED CASNP/INSULIN/C10 NANOCONSTRUCT AND ENCAPSULATED INSULIN WILL BE LABELED WITH NEAR INFRARED (NIR) FLUORESCENT DYES FOR NON-INVASIVE TRACKING OF CASNP/INSULIN/C10 DELIVERY AND THE SUBSEQUENT INSULIN RELEASE AND ABSORPTION IN THE STREPTOZOTOCIN (STZ) INDUCED DIABETIC MOUSE MODEL. WE WILL PREPARE AND OPTIMIZE THE CASNP/INSULIN/C10 FORMULATION WITH DESIRED PHYSIOCHEMICAL AND BIOLOGICAL PROPERTIES, INCLUDING INSULIN AND C10 LOADING CAPACITIES, STABILITY IN THE SIMULATED GASTRIC CONDITION AND CONTROLLED RELEASE IN THE INTESTINE-MIMICKING CONDITION (AIM 1). WE WILL DETERMINE THE BIODISTRIBUTION OF CASNP/INSULIN/C10, PLASMA AND HEPATIC INSULIN BIOAVAILABILITY AND THE SYSTEMIC CYTOTOXICITY IN STZ-INDUCED DIABETIC MICE USING NIR AND MAGNETIC RESONANCE IMAGING ALONG WITH HISTOPATHOLOGICAL ANALYSES AND VALIDATION, FOLLOWED BY EVALUATING THE EFFICACY OF CASNP/INSULIN/C10 IN CONTROLLING HYPERGLYCEMIA (AIM 2).
$299,931
PROJECT GRANT (B)
Feb 16, 2024
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
CANCER TREATMENT RESEARCH
A NEW CLASS OF MAGNETIC NANOPARTICLES FOR GLIOMA TARGETED DRUG DELIVERY - PROJECT SUMMARY GLIOBLASTOMA IS THE MOST COMMON AND AGGRESSIVE MALIGNANT BRAIN TUMOR WITH EXTREMELY POOR PROGNOSIS. CURRENT STANDARD CARE FOR GLIOBLASTOMA TREATMENT CONSISTS OF MAXIMAL SURGICAL RESECTION FOLLOWED BY CHEMOTHERAPY AND RADIATION THERAPY. UNFORTUNATELY, IT HARDLY PRODUCES LONG-TERM CONTROL ON TUMOR PROGRESSION. DUE TO THE HIGHLY HETEROGENEOUS, INFILTRATING AND RECURRING NATURES OF GLIOBLASTOMAS, CHEMOTHERAPY PLAYS A CRUCIAL ROLE IN CLINICAL MANAGEMENT OF GLIOBLASTOMAS. HOWEVER, EXISTING CHEMOTHERAPIES IN BRAIN TUMOR TREATMENT ARE MOSTLY DISAPPOINTING, OFTEN DUE TO POOR DELIVERY OF CHEMOTHERAPY AGENTS STEMMING FROM THEIR LOW WATER SOLUBILITY AND/OR INABILITY OF CROSSING THE BLOOD BRAIN BARRIER (BBB) OR BLOOD TUMOR BARRIER (BTB). ALTHOUGH NANOMATERIAL-BASED DRUG DELIVERY SYSTEMS HAVE SHOWN ADVANTAGES BY ENHANCING THE DELIVERY EFFICIENCY AND IMPROVING THE SAFETY PROFILE OF THERAPEUTICS OVER CONVENTIONAL CHEMOTHERAPY FORMULATIONS IN TREATING MANY CANCERS, THEIR DEVELOPMENT AND APPLICATIONS IN BRAIN TUMOR TREATMENT ARE LARGELY LIMITED, BECAUSE OF DELIVERY CHALLENGES IN CURRENT NANO-DELIVERY SYSTEMS WITH SIZES OF 10-200 NM. SUPPORTED BY THE PREMISES THAT: 1) FERUMOXYTOL (FERAHEME®), AN FDA APPROVED IRON OXIDE NANOPARTICLE FOR TREATING IRON DEFICIENCY ANEMIA, CAN BE USED FOR IMAGING BRAIN TUMOR WITH MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS, AND 2) OUR SUB-5 NM ULTRAFINE IRON OXIDE NANOPARTICLE (UIONP) CAN REACH BRAIN TUMORS IN THE INTRACRANIAL GLIOMA MOUSE MODEL TO ENHANCE TUMORS IN MRI WITH T1 CONTRAST, THIS STTR PHASE I PROJECT AIMS TO DEVELOP A NEW CLASS OF DRUG-CARRYING AND GLIOBLASTOMA TARGETED IONP FOR DELIVERING HIGHLY POTENT YET WATER-INSOLUBLE CHEMOTHERAPY AGENT SN38, THE ACTIVE AND MUCH MORE POTENT FORM OF CHEMOTHERAPY AGENT IRINOTECAN (CPT-11) USED IN TREATING MANY OTHER CANCERS IN ONCOLOGY CLINIC, FOR TREATING INTRACRANIAL BRAIN TUMORS. WE WILL INCORPORATE OUR PATENTED AMPHIPHILIC POLY(ETHYLENE GLYCOL)-BLOCK-(ALLYL GLYCIDYL ETHER) (PEG-B-AGE) COATING POLYMER FOR UIONPS TO ENCAPSULATE HYDROPHOBIC SN38, WHICH HAS NOT BEEN USED FOR TREATING BRAIN TUMORS DUE TO POOR INTRACRANIAL DELIVERY. TRI-PEPTIDE RGD WITH WELL-DOCUMENTED FUNCTIONS AND SAFETY PROFILE IS SELECTED AS THE LIGAND FOR FUNCTIONALIZING UIONPS TO TARGET ΑVΒ3 INTEGRIN OVEREXPRESSED IN GLIOBLASTOMAS. IN THE PROPOSED PROJECT, WE WILL PREPARE AND OPTIMIZE THE RGD-CONJUGATED UIONP WITH SN38 LOADING (RGD-UIONP/SN38) WITH CONSISTENT PHYSIOCHEMICAL AND BIOLOGICAL PROPERTIES, INCLUDING SN38 LOADING EFFICIENCY, SURFACE CHARGE, DENSITY OF CONJUGATED THE TARGETING LIGAND, GLIOBLASTOMA CELL TARGETING, INTRACELLULAR DRUG RELEASE AND CYTOTOXICITY, AND STABILITY (AIM 1). WE WILL THEN USE AN INTRACRANIAL MOUSE MODEL TO INVESTIGATE THE BLOOD HALF-LIFE, BIODISTRIBUTION, CLEARANCE, AND TUMOR UPTAKE AND INTRA-TUMORAL DISTRIBUTION OF DEVELOPED RGD-UIONP/SN38 AS WELL AS THE STABILITY OF THIS PLATFORM IN BLOOD AND ORGANS IN AIM 2, FOLLOWED BY DETERMINING THE EFFICACY OF RGD- UIONP/SN38 IN INHIBITING THE TUMOR GROWTH BASED ON MRI IN VIVO AND HISTOPATHOLOGICAL ANALYSIS. THE RESULTS WILL LEAD TO THE FURTHER DEVELOPMENT OF THIS SYSTEM TOWARDS CLINICAL TRANSLATION IN THE PHASE II PROJECT.
$400,000
PROJECT GRANT (B)
Jan 11, 2024
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
AGING RESEARCH
HIGHLY SENSITIVE AND ROBUST BLOOD TEST PLATFORM FOR SCREENING AND EARLY DETECTION OF ALZHEIMER'S DISEASE - WITH AN EFFECTIVE TREATMENT YET TO BE DEVELOPED, EARLY DETECTION AND SURVEILLANCE OF DISEASE PROGRESSION FOR ALZHEIMER’S DISEASE (AD) AND ALZHEIMER’S DISEASE RELATED DEMENTIAS (ADRD) ARE CRITICAL FOR THE MANAGEMENT AND INTERVENTION OF AD/ADRD. THE RECENT ACCELERATED APPROVAL OF THE NEW MONOCLONAL ANTIBODY DRUG TARGETING AMYLOID-Β, ADUCANUMAB®, BY FDA, WHICH IS LIKELY MORE EFFICACIOUS WHEN TREATING PROPERLY STRATIFIED PATIENTS, HIGHLIGHTED THE URGENT CLINICAL NEED FOR EARLY AND BIOMARKER-SPECIFIC DIAGNOSIS OF AD. CURRENT CLINICAL PRACTICES WITH AD BIOMARKER TARGETED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AND CEREBROSPINAL FLUID (CSF) SAMPLE BASED PROTEOMICS ANALYSIS ARE NOT DESIRABLE POINT-OF-CARE (POC) SOLUTIONS FOR EARLY DETECTION DUE TO THE LIMITED AVAILABILITY AND ACCESSIBILITY OF IMAGING FACILITIES OR INVASIVE LUMBAR PUNCTURE FOR CSF COLLECTION. GIVEN THE ADVANTAGES OF NON-INVASIVENESS, COST EFFECTIVENESS AND EASY ACCESS IN GENERAL CLINICAL SETTINGS, BLOOD-BASED AD BIOMARKER DETECTIONS ARE MORE APPLICABLE POC DIAGNOSTIC TOOLS FOR EARLY DIAGNOSIS OF AD/ADRD. WHILE TWO PLATFORMS, I.E., PRECIVITYADTM FOR AΒ40/AΒ42 DETECTION AND SIMOA® FOR PHOSPHO-TAU 181 (P-TAU181), WERE RECENTLY GRANTED FDA BREAKTHROUGH DEVICE DESIGNATIONS FOR CLINICAL USES, BOTH SYSTEMS REQUIRE HIGHLY SPECIALIZED HIGH-END INSTRUMENTS FOR SAMPLE TESTING, LIMITING THEIR WIDE AVAILABILITY, PARTICULARLY IN THE COMMUNITIES AND REGIONS WITH LOW OR LIMITED RESOURCES AND HEALTH DISPARITY. FURTHERMORE, PRECIVITYADTM AND SIMOA® USE ANTIBODY-COATED MAGNETIC BEADS TO CAPTURE TARGETED AD BIOMARKERS. HOWEVER, THE NON-SPECIFIC ADSORPTION OF SERUM PROTEINS ON THE SURFACE OF BEADS FORMS A PROTEIN CORONA THAT CAN BLOCK THE ANTIBODY FROM CAPTURING BIOMARKERS. IN THIS SBIR PHASE I PROJECT, WE AIM TO DEVELOP A MULTIPLEXED AD BIOMARKER DETECTION PLATFORM THAT CAN INTEGRATE TWO INNOVATIVE TECHNOLOGIES, I.E., ULTRAMAGNETIC IRON OXIDE NANORODS (IONRS) AND ANTI-BIOFOULING POLYMER COATING FOR IONRS, FOR MULTIPLEXING SIX AD BIOMARKERS IN BLOOD SAMPLES. THE IONRS PROVIDE AS STRONG MAGNETISM AS THE MAGNETIC BEADS USED IN PRECIVITYADTM AND SIMOA®, AND ALSO FUNCTION AS NANO-STIRRING-BARS TO IMPROVE SAMPLE MIXING, UNDER AN ALTERNATING ELECTROMAGNETIC FIELD, FOR MORE EFFICIENT BIOMARKER CAPTURING. THE ANTI-BIOFOULING COATING MINIMIZES NON-SPECIFIC SERUM PROTEIN ADSORPTION ON IONRS TO PRESERVE THE ANTIBODY AFFINITY FOR TARGETED BIOMARKERS IN BLOOD SAMPLES. THE PHASE I PROJECT WILL FOCUS ON (1) DEVELOPING A PROTOTYPE DEVICE ENABLING EFFICIENT BLOOD SAMPLE MIXING WITH ANTI-BIOFOULING IONRS AND MULTIPLEXED DETECTION OF SIX AD BIOMARKERS, I.E., AΒ40, AΒ42, TOTAL-TAU (T-TAU), P-TAU181, AMYLOID PRECURSOR PROTEIN (APP669-711), AND NEUROFILAMENT LIGHT PROTEIN (NFL), AND (2) TESTING THE DEVELOPED SYSTEM AND EVALUATE ITS PERFORMANCE USING THE PATIENT SAMPLES, FOLLOWED BY COMPARING AND CORRELATING THE RESULTS WITH CLINICAL DIAGNOSIS AND IMAGING FINDINGS OF THE SAME PATIENTS. IF SUCCESSFUL, THE DEVICE, TO BE FURTHER ASSESSED BY LARGE-SCALE TESTS IN PHASE II, WILL PROVIDE A ROBUST AND COST-EFFECTIVE POC DETECTION FOR SCREENING AND DETECTING AD IN INDIVIDUALS AT RISK AS WELL AS SURVEILLING THE PROGRESSION AND TREATMENT RESPONSE FOR PATIENTS.
$399,840
PROJECT GRANT (B)
Aug 6, 2024
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
AGING RESEARCH
HIGHLY SENSITIVE AND ROBUST BLOOD TEST PLATFORM FOR SCREENING AND EARLY DETECTION OF ALZHEIMER'S DISEASE - WITH AN EFFECTIVE TREATMENT YET TO BE DEVELOPED, EARLY DETECTION AND SURVEILLANCE OF DISEASE PROGRESSION FOR ALZHEIMER’S DISEASE (AD) AND ALZHEIMER’S DISEASE RELATED DEMENTIAS (ADRD) ARE CRITICAL FOR THE MANAGEMENT AND INTERVENTION OF AD/ADRD. THE RECENT ACCELERATED APPROVAL OF THE NEW MONOCLONAL ANTIBODY DRUG TARGETING AMYLOID-Β, ADUCANUMAB®, BY FDA, WHICH IS LIKELY MORE EFFICACIOUS WHEN TREATING PROPERLY STRATIFIED PATIENTS, HIGHLIGHTED THE URGENT CLINICAL NEED FOR EARLY AND BIOMARKER-SPECIFIC DIAGNOSIS OF AD. CURRENT CLINICAL PRACTICES WITH AD BIOMARKER TARGETED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AND CEREBROSPINAL FLUID (CSF) SAMPLE BASED PROTEOMICS ANALYSIS ARE NOT DESIRABLE POINT-OF-CARE (POC) SOLUTIONS FOR EARLY DETECTION DUE TO THE LIMITED AVAILABILITY AND ACCESSIBILITY OF IMAGING FACILITIES OR INVASIVE LUMBAR PUNCTURE FOR CSF COLLECTION. GIVEN THE ADVANTAGES OF NON-INVASIVENESS, COST EFFECTIVENESS AND EASY ACCESS IN GENERAL CLINICAL SETTINGS, BLOOD-BASED AD BIOMARKER DETECTIONS ARE MORE APPLICABLE POC DIAGNOSTIC TOOLS FOR EARLY DIAGNOSIS OF AD/ADRD. WHILE TWO PLATFORMS, I.E., PRECIVITYADTM FOR AΒ40/AΒ42 DETECTION AND SIMOA® FOR PHOSPHO-TAU 181 (P-TAU181), WERE RECENTLY GRANTED FDA BREAKTHROUGH DEVICE DESIGNATIONS FOR CLINICAL USES, BOTH SYSTEMS REQUIRE HIGHLY SPECIALIZED HIGH-END INSTRUMENTS FOR SAMPLE TESTING, LIMITING THEIR WIDE AVAILABILITY, PARTICULARLY IN THE COMMUNITIES AND REGIONS WITH LOW OR LIMITED RESOURCES AND HEALTH DISPARITY. FURTHERMORE, PRECIVITYADTM AND SIMOA® USE ANTIBODY-COATED MAGNETIC BEADS TO CAPTURE TARGETED AD BIOMARKERS. HOWEVER, THE NON-SPECIFIC ADSORPTION OF SERUM PROTEINS ON THE SURFACE OF BEADS FORMS A PROTEIN CORONA THAT CAN BLOCK THE ANTIBODY FROM CAPTURING BIOMARKERS. IN THIS SBIR PHASE I PROJECT, WE AIM TO DEVELOP A MULTIPLEXED AD BIOMARKER DETECTION PLATFORM THAT CAN INTEGRATE TWO INNOVATIVE TECHNOLOGIES, I.E., ULTRAMAGNETIC IRON OXIDE NANORODS (IONRS) AND ANTI-BIOFOULING POLYMER COATING FOR IONRS, FOR MULTIPLEXING SIX AD BIOMARKERS IN BLOOD SAMPLES. THE IONRS PROVIDE AS STRONG MAGNETISM AS THE MAGNETIC BEADS USED IN PRECIVITYADTM AND SIMOA®, AND ALSO FUNCTION AS NANO-STIRRING-BARS TO IMPROVE SAMPLE MIXING, UNDER AN ALTERNATING ELECTROMAGNETIC FIELD, FOR MORE EFFICIENT BIOMARKER CAPTURING. THE ANTI-BIOFOULING COATING MINIMIZES NON-SPECIFIC SERUM PROTEIN ADSORPTION ON IONRS TO PRESERVE THE ANTIBODY AFFINITY FOR TARGETED BIOMARKERS IN BLOOD SAMPLES. THE PHASE I PROJECT WILL FOCUS ON (1) DEVELOPING A PROTOTYPE DEVICE ENABLING EFFICIENT BLOOD SAMPLE MIXING WITH ANTI-BIOFOULING IONRS AND MULTIPLEXED DETECTION OF SIX AD BIOMARKERS, I.E., AΒ40, AΒ42, TOTAL-TAU (T-TAU), P-TAU181, AMYLOID PRECURSOR PROTEIN (APP669-711), AND NEUROFILAMENT LIGHT PROTEIN (NFL), AND (2) TESTING THE DEVELOPED SYSTEM AND EVALUATE ITS PERFORMANCE USING THE PATIENT SAMPLES, FOLLOWED BY COMPARING AND CORRELATING THE RESULTS WITH CLINICAL DIAGNOSIS AND IMAGING FINDINGS OF THE SAME PATIENTS. IF SUCCESSFUL, THE DEVICE, TO BE FURTHER ASSESSED BY LARGE-SCALE TESTS IN PHASE II, WILL PROVIDE A ROBUST AND COST-EFFECTIVE POC DETECTION FOR SCREENING AND DETECTING AD IN INDIVIDUALS AT RISK AS WELL AS SURVEILLING THE PROGRESSION AND TREATMENT RESPONSE FOR PATIENTS.
$399,840
PROJECT GRANT (B)
Feb 10, 2025
5m Biomed, LLC
670 Lake Medlock Dr
Department of Health and Human Services / National Institutes of Health
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH
SMALL INTESTINE TARGETED FAST ACTING ORAL INSULIN FORMULATION - PROJECT SUMMARY DIABETES MELLITUS IS A CLASS OF METABOLIC DISEASES CHARACTERIZED BY CHRONIC HYPERGLYCEMIA DUE TO IMPAIRED INSULIN SECRETION AND/OR INSULIN RESISTANCE. PATIENTS ARE SUBJECT TO LIFE-LONG MANAGEMENT OF THEIR DIABETIC CONDITIONS AND THE HIGH RISK OF MACRO AND MICROVASCULAR COMPLICATIONS. INSULIN THERAPY IS THE MOST EFFECTIVE MEANS OF LOWERING BLOOD GLUCOSE FOR TYPE 1 DIABETES MELLITUS (T1DM) PATIENTS WITH COMPLETE ABSENCE OF ENDOGENOUS INSULIN AND TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS WITH PROGRESSIVELY DEPLETED INSULIN SECRETING PANCREATIC Β-CELLS AND INSULIN RESISTANT ORGANS AND TISSUE. IT IS ALSO USED FOR CONTROLLING SHORT-TERM HYPERGLYCEMIA IN GESTATIONAL DIABETES MELLITUS (GDM). THE CURRENT THERAPY IS SUBCUTANEOUS INJECTION OR INFUSION OF INSULIN. HOWEVER, THE POOR PATIENT ADHERENCE DUE TO INCONVENIENCE AND PSYCHOLOGICAL INSULIN RESISTANCE (PIR) TO ROUTINE INJECTION IS STILL A MAJOR HINDRANCE IN MANAGING DIABETIC PATIENTS. FURTHERMORE, LONG- TERM USE OF INSULIN INJECTION CAN CAUSE SIDE EFFECTS, INCLUDING LIPODYSTROPHY, IATROGENIC HYPERINSULINEMIA, AND HYPOGLYCEMIA. ORALLY DELIVERED INSULIN, ON THE OTHER HAND, POSSESSES ADVANTAGES IN PATIENT ADHERENCE AND THERAPEUTIC EFFECT BY MIMICKING THE PHYSIOLOGICAL PATH OF ENDOGENOUS INSULIN. HOWEVER, THE DEVELOPMENT OF ORAL INSULIN FORMULATIONS HAS NOT YET BEEN SUCCESSFUL DUE TO LOW INSULIN BIOAVAILABILITY, STEMMING FROM THE DEGRADATION IN THE HIGHLY ACIDIC AND PROTEASE-ACTIVE STOMACH AND INSUFFICIENT PERMEABILITY THROUGH THE INTESTINAL EPITHELIUM AND MUCOSA. THIS STTR PHASE I PROJECT AIMS TO DEVELOP A FAST-ACTING ORAL INSULIN FORMULATION BASED ON THE PATENTED INNOVATION OF MILK PROTEIN CASEIN COATED DRUG-CARRYING NANOPARTICLES (CASNP) TO ENCAPSULATE INSULIN AND THE INTESTINAL ABSORPTION ENHANCER, SODIUM CAPRATE (C10), FOR SMALL INTESTINE-TARGETED DELIVERY OF INSULIN BY PROTECTING INSULIN AND C10 FROM THE GASTRIC PH AND PROTEASE ACTION BUT ENABLING THE ENZYME-TRIGGERED RELEASE OF INSULIN AND C10 IN THE SMALL INTESTINE. THE LIQUID FORMULATION OF NANO-SIZED CASNP/INSLULIN/C10 ALSO FACILITATES RAPID GASTRIC EMPTYING AND INTESTINAL PERMEATION AND ABSORPTION AS EXPECTED IN A FAST-ACTING ORAL INSULIN AGENT FOR CONTROLLING THE POSTPRANDIAL BLOOD GLUCOSE LEVELS. DEVELOPED CASNP/INSULIN/C10 NANOCONSTRUCT AND ENCAPSULATED INSULIN WILL BE LABELED WITH NEAR INFRARED (NIR) FLUORESCENT DYES FOR NON-INVASIVE TRACKING OF CASNP/INSULIN/C10 DELIVERY AND THE SUBSEQUENT INSULIN RELEASE AND ABSORPTION IN THE STREPTOZOTOCIN (STZ) INDUCED DIABETIC MOUSE MODEL. WE WILL PREPARE AND OPTIMIZE THE CASNP/INSULIN/C10 FORMULATION WITH DESIRED PHYSIOCHEMICAL AND BIOLOGICAL PROPERTIES, INCLUDING INSULIN AND C10 LOADING CAPACITIES, STABILITY IN THE SIMULATED GASTRIC CONDITION AND CONTROLLED RELEASE IN THE INTESTINE-MIMICKING CONDITION (AIM 1). WE WILL DETERMINE THE BIODISTRIBUTION OF CASNP/INSULIN/C10, PLASMA AND HEPATIC INSULIN BIOAVAILABILITY AND THE SYSTEMIC CYTOTOXICITY IN STZ-INDUCED DIABETIC MICE USING NIR AND MAGNETIC RESONANCE IMAGING ALONG WITH HISTOPATHOLOGICAL ANALYSES AND VALIDATION, FOLLOWED BY EVALUATING THE EFFICACY OF CASNP/INSULIN/C10 IN CONTROLLING HYPERGLYCEMIA (AIM 2).
$299,931
PROJECT GRANT (B)
Oct 16, 2024

Schools & Education

Part of Fulton County School District. 3 nearby schools serving this area.

E
Elementary

Creek View Elementary School

Score 69/100
Enrollment 980
Distance 0.3 mi
M
Middle

Autrey Mill Middle School

Score 69/100
Enrollment 1,421
Distance 0.2 mi
H
High School

Alpharetta High School

Enrollment 2,031
Distance 1.0 mi

Source: National Center for Education Statistics (NCES) · Updated Feb 2026

At a Glance

Avg Home Value
$583,005
Est. Monthly Cost
$3,191
$2,948 mortgage · N/A tax
Best School
69/100
3 nearby schools
Stability
Stable
55/100
57 homes · 1 street

Lake Medlock Dr exhibits moderate stability with a mix of long-term and newer residents.

Continue Your Research

Frequently Asked Questions

What is the average home value in Lake Medlock Dr?
The average assessed property value in Lake Medlock Dr is $583,005, with average annual property taxes of N/A.
What school district is Lake Medlock Dr in?
Lake Medlock Dr is served by Fulton County School District. The highest-rated nearby school scores 69/100.
How many homes are in Lake Medlock Dr?
Lake Medlock Dr in Alpharetta, GA has 57 homes across 1 street.
Is Lake Medlock Dr good for families?
Lake Medlock Dr is served by Fulton County School District (top school score: 69/100), average home value of $583,005. The neighborhood has 57 homes across 1 street, providing a sizeable community for families.
How much does it cost to live in Lake Medlock Dr?
The average assessed home value is $583,005, and the estimated total monthly housing cost (mortgage, taxes, and insurance) is approximately $3,191. These estimates are based on a 30-year mortgage at 6.5% with 20% down.
What elementary school serves Lake Medlock Dr?
The nearest elementary school is Creek View Elementary School, located 0.3 miles away. It has 980 students enrolled.
What high school serves Lake Medlock Dr?
The nearest high school is Alpharetta High School, located 1.0 miles away.
Is Lake Medlock Dr a stable neighborhood?
Lake Medlock Dr has a stability score of 55/100, classified as "Stable." This indicates moderate stability with some residential turnover.

Data Sources & Methodology

6 verified data sources power this report

Property tax & valuation records

Federal education statistics

Healthcare facility & outcome data

Transportation & hazard data

5-year community survey estimates

Housing market indicators

Last updated:

View full methodology

Get Neighborhood Updates

Stay informed about changes in Lake Medlock Dr.